Reposting some useful information from "that other board"

New Post Public Reply Private Reply Replies (1) Message Board
mtruong34
734
Reposting some useful information from "that other board" regarding unblinding & data analysis.

"Hi Everyone, I am long time reader of this board but just created my account to clarify some of the technicalities regarding the unblinding process. I am statistical programmer, worked on numerous topline reports and was part of 3 successful BLAs in my short career of 10 years.

01/13 is the last patient last visit day which is not the same as unblinding. As Rockleo pointed out the sites will have 24hrs to enter the data in to the EDC system. Data monitoring and Data cleaning will be performed and queriers will be raised and the sites will have to respond to those queries. There is vendor data to be finalized as well. The safety labs, cytokine panels etc all come from the vendors. Each and every data point has to be reconciled and the database has to be locked. Pandemic or No pandemic the FDA is very strict about Data Integrity. If there are any mistakes during this process, the database has to be unlocked, corrected and locked. Trust me nobody wants to go through that.

Once the database is unlocked, unblinding will be authorized and statistical analysis is done. There are multiple steps in this process. The raw data from the EDC and vendors need to be standardized into SDTM and ADaM formats for analysis. The FDA only accepts SDTM and ADaM datasets and every step has to be validated. The programming to do this should already be in place and if Amarex is competent the whole process should not take more than a couple of days. Usually the sponsor which in this case Cytodyn has a dedicated team working on this producing the Topline report.

In short if AMAREX is on top of everything, we should be able to hear something sometime by mid to end of next week which is my most optimistic estimate. If they are bit sloppy it will add an additional week or two.

The FDA knows this clearly and it might be the reason for the authorization of Open label cohort.

Respect for all the senior members of this board. Rockleo, Black-ops and many others.

One more point i would like to make is regarding the no of deaths.

At 50% DSMC review we were told 45 deaths were on the trial but it was not broken down to how many deaths were within 28 days. The DSMC came back saying we would like to do a review at 75% and also want to look at Day 42. This is because some of the deaths were post Day 28 and they wanted to include these as well which might push us towards statistical significance.
If there was no separation from Placebo in terms of efficacy, the trial would have been stopped by the DSMC and everyone knows that.

For every trial, there will be a safety and pharmacovigilance group monitoring the SAEs and deaths. They have to report the unblinded case reports of the patients who died to the FDA immediately with in 24 hrs. The FDA will stop the trail if they see anything unusual.

Now we know there are 87 deaths and we know there will be more. It is sad to say this but the more no of deaths, the better chance to have a positive outcome.

Does everyone think Nader gave out that number because someone posted a random question and he was innocently answering that. Wrong. I was asking for this number prior to every conference call which was never answered. Cytodyn/Nader puts it out there only when they want to do it. They know it is very favourable to the drug and that's the reason they gave out that number in the last conference call.

Being said that, all of the above point to Clinical significance. Whether it shows statistical significance is what remains to be seen. the FDA knows that hence the billing codes were given and the open label cohort was initiated.

In this pandemic nobody is looking for statistical significance. For an EUA the FDA needs a well conducted trial with a decent sample size. For CD10 the sample size is very low. We only had 45 subjects with a total symptom score >=4. As Rockleo pointed out, you cannot treat subjects who don't have enough symptoms and expect them to show reduction in symptoms. All treatments which received EUA had completed their trials with enough sample size which we are on the verge of doing."

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 10

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Antonio Filosa Takes the Helm as CEO of Stellantis N.V.

Updated Category News Views 335

Antonio Filosa Appointed as Stellantis N.V. Chief Executive Officer Stellantis N.V., a prominent player in the global automotive arena, has officially announced the appointment of Antonio Filosa as its new Chief Executive Officer. Filosa, who has amassed over 25 years of experience within the automotive sector, currently holds the position of Chief Operating Officer for...

Continue Reading
Understanding the Edwards Lifesciences Legal Landscape

Updated Category News Views 278

Understanding Recent Legal Issues for Investors In the world of investment, understanding legal implications can often feel overwhelming, especially when a company faces a class action lawsuit. Edwards Lifesciences Corporation, a name recognized for its innovative heart valve technologies, currently finds itself embroiled in legal battles that could shape its future and...

Continue Reading
Arrive Home and FormFree Join Forces to Enhance Homeownership Access

Updated Category News Views 155

Arrive Home Partners with FormFree for Innovative Solutions The innovative collaboration between Arrive Home and FormFree aims to transform the landscape of homeownership for many borrowers facing challenges due to limited credit histories. This partnership is particularly significant as it opens doors for those who have previously been overlooked by traditional credit...

Continue Reading
Verizon's $20 Billion Acquisition: A Strategic Expansion Ahead

Updated Category News Views 76

Verizon Announces Major Acquisition of Frontier Communications Verizon has recently made headlines by announcing a significant acquisition deal with Frontier Communications. This all-cash transaction, valued at $20 billion, underscores Verizon's dedication to substantially expanding its fiber network. Details of the Acquisition According to the proposed terms, Verizon...

Continue Reading
MoxiWorks Enhances Innovation Timeline with New Leadership and Funding

Updated Category News Views 174

MoxiWorks Enhances Innovation Timeline with New Leadership and Funding Funding from private equity and brokerage partners, along with new leadership, is set to transform MoxiWorks, a leading provider of sales and marketing software in the real estate sector. With substantial capital secured from its ownership group, which includes Vector Capital, Howard Hanna Real Estate...

Continue Reading